WO2006077232A3 - Multimeric soluble fas ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation - Google Patents

Multimeric soluble fas ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation Download PDF

Info

Publication number
WO2006077232A3
WO2006077232A3 PCT/EP2006/050300 EP2006050300W WO2006077232A3 WO 2006077232 A3 WO2006077232 A3 WO 2006077232A3 EP 2006050300 W EP2006050300 W EP 2006050300W WO 2006077232 A3 WO2006077232 A3 WO 2006077232A3
Authority
WO
WIPO (PCT)
Prior art keywords
transplantation
lymphocyte
harmatopoietic
allogenic
stem
Prior art date
Application number
PCT/EP2006/050300
Other languages
French (fr)
Other versions
WO2006077232A2 (en
Inventor
Marc Dupuis
Stephane Demotz
Peter Greaney
Antoine Attinger
Severine Perrod
Original Assignee
Apoxis Sa
Marc Dupuis
Stephane Demotz
Peter Greaney
Antoine Attinger
Severine Perrod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoxis Sa, Marc Dupuis, Stephane Demotz, Peter Greaney, Antoine Attinger, Severine Perrod filed Critical Apoxis Sa
Publication of WO2006077232A2 publication Critical patent/WO2006077232A2/en
Publication of WO2006077232A3 publication Critical patent/WO2006077232A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention concerns novel approaches for eliminating activated allo-reactive T lymphocyte in vivo and in vitro, preventing GVHD development with a sufficient amount of a multimeric form of the soluble portion of FasL as defined below.
PCT/EP2006/050300 2005-01-20 2006-01-19 Multimeric soluble fas ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation WO2006077232A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64529005P 2005-01-20 2005-01-20
US60/645,290 2005-01-20

Publications (2)

Publication Number Publication Date
WO2006077232A2 WO2006077232A2 (en) 2006-07-27
WO2006077232A3 true WO2006077232A3 (en) 2007-05-24

Family

ID=36579799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/050300 WO2006077232A2 (en) 2005-01-20 2006-01-19 Multimeric soluble fas ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation

Country Status (1)

Country Link
WO (1) WO2006077232A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135615A1 (en) * 2001-07-21 2003-02-06 Genethor Gmbh Treatment of antigen-presenting cells or their precursors, useful e.g. in treatment of leukemia, by suppressing allologous immune responses to tissue grafts
US20030053984A1 (en) * 1999-12-30 2003-03-20 Jurg Tschopp Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
US20040131599A1 (en) * 2002-03-13 2004-07-08 Civin Curt I Fas ligand expressing hematopoietic cells for transplantation
EP1481687A1 (en) * 2003-05-26 2004-12-01 Apoxis SA Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030053984A1 (en) * 1999-12-30 2003-03-20 Jurg Tschopp Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
DE10135615A1 (en) * 2001-07-21 2003-02-06 Genethor Gmbh Treatment of antigen-presenting cells or their precursors, useful e.g. in treatment of leukemia, by suppressing allologous immune responses to tissue grafts
US20040131599A1 (en) * 2002-03-13 2004-07-08 Civin Curt I Fas ligand expressing hematopoietic cells for transplantation
EP1481687A1 (en) * 2003-05-26 2004-12-01 Apoxis SA Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOLLER NILS ET AL: "Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 23, no. 4, February 2003 (2003-02-01), pages 1428 - 1440, XP002258597, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
WO2006077232A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2007090127A3 (en) Compressible intravascular embolization particles and related methods and delivery systems
EP2244729A4 (en) Cysteine engineered antibodies for site-specific conjugation
WO2006126219A8 (en) Liver progenitor cells
WO2011022509A3 (en) Substituted benzoazepines as toll-like receptor modulators
WO2011022508A3 (en) Substituted benzoazepines as toll-like receptor modulators
WO2005087808A3 (en) Growth factor binding constructs materials and methods
WO2008019368A3 (en) Albumin-insulin fusion proteins
WO2007129323A3 (en) Device and method for vascular filter
WO2008031045A3 (en) Aquaretic and natriuretic polypeptides lacking vasodilatory activity
WO2011011484A3 (en) Particulate tissue graft with components of differing density and methods of making and using the same
TW200720076A (en) Composite materials and methods of making the same
EP1904625A4 (en) Microscale micropatterned engineered in vitro tissue
EP3199551A3 (en) Fully human antibodies to btla
WO2007062243A3 (en) Serum-free expansion of cells in culture
IL187503A0 (en) Stable and soluble antibodies
EP1919703A4 (en) Compositionally modulated composite materials and methods for making the same
WO2006094286A3 (en) Adult pancreatic derived stromal cells
NZ602484A (en) Composite additive materials
LT1868635T (en) Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
WO2006108670A3 (en) Use of cd25 antibodies in immunotherapy
WO2006107850A3 (en) Preventing rejection of transplanted tissue using regulatory t cells
WO2007145672A3 (en) Combinations of human proteins to enhance viability of stem cells and progenitor cells
WO2008094599A3 (en) Modified rna ligase for efficient 3' modification of rna
MY146352A (en) Adipose derived adult stem cells in hepatic regeneration
PL1844661T3 (en) Stabilized enzyme compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 30.10.2007

122 Ep: pct application non-entry in european phase

Ref document number: 06704252

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6704252

Country of ref document: EP